0001493152-22-007157.txt : 20220317 0001493152-22-007157.hdr.sgml : 20220317 20220317161545 ACCESSION NUMBER: 0001493152-22-007157 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220315 FILED AS OF DATE: 20220317 DATE AS OF CHANGE: 20220317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fremeau Robert Thomas Jr. CENTRAL INDEX KEY: 0001894066 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35817 FILM NUMBER: 22748712 MAIL ADDRESS: STREET 1: C/O VYANT BIO, INC. STREET 2: 2370 STATE ROUTE 70 WEST, SUITE 310 CITY: CHERRY HILL STATE: NJ ZIP: 08002 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vyant Bio, Inc. CENTRAL INDEX KEY: 0001349929 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 043462475 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 BUSINESS PHONE: 201.528.9200 MAIL ADDRESS: STREET 1: 2370 STATE ROUTE 70 WEST STREET 2: SUITE 310 CITY: CHERRY HILL, STATE: NJ ZIP: 08002 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS, INC DATE OF NAME CHANGE: 20111216 FORMER COMPANY: FORMER CONFORMED NAME: CANCER GENETICS INC DATE OF NAME CHANGE: 20060117 4 1 ownership.xml X0306 4 2022-03-15 0 0001349929 Vyant Bio, Inc. VYNT 0001894066 Fremeau Robert Thomas Jr. C/O VYANT BIO, INC. 2 EXECUTIVE CAMPUS 2370 STATE ROUTE 70, SUITE 310 CHERRY HILL, NJ 08002 0 1 0 0 Chief Scientific Officer Stock option (right to buy) 1.00 2022-03-15 4 A 0 75000 0 A 2032-03-15 Common Stock 75000 75000 D The option shall become exercisable with respect to twenty five percent (25%) of the shares underlying the option upon the date of grant, with respect to thirty seven and a half percent (37.5)% upon the filing by the Company of an Investigational New Drug Application ("IND") with the U.S. Food and Drug Administration ("FDA") for a New Chemical Entity ("NCE") candidate to treat Rett Syndrome and with respect to the remaining thirty seven and a half percent (37.5)% upon the filing by the Company of an IND with the FDA for an NCE candidate to treat CDKL5 Deficiency Disorders; provided that the participant remains a service provider to the Company through each applicable vesting date. /s/ Andrew LaFrence, attorney-in-fact 2022-03-17